


# MONOCLONAL ANTIBODY



## TENASCIN-C clone DB7 (IgG<sub>2a</sub>)

### Background

The extracellular matrix (ECM) consists of interstitial connective tissue and basement membrane (BM). The ECM acts as a backbone for cells and provides a physical barrier. It also influences such functions as cell proliferation, differentiation, adhesion, migration, gene expression, and tissue integrity. ECM also plays a profound role in tissue injury and healing. The detection of ECM components in various parts of the body provides an efficient tool for following malignant change, invasion and metastasis. Biohit provides monoclonal antibodies to fibronectins, tenascin, and laminin. and vitronectin.

The product is for research use only. The performance characteristics of this product have not been established. Use in human clinical diagnosis is the responsibility of the user. This product should be stored at +2 to +8 °C. Monoclonal antibody to tenascin is derived from the hybridoma produced by fusion between myeloma cells and Balb/c spleen cells. Tenascin polypeptides isolated from spent culture supernatant of human fibroblasts isolated by affinity chromatography were used as immunogen.

Cat. No. 610003	100 µg immunoglobulin in 1 ml PBS solution containing 1.0% (w/v) BSA and 0.09% (w/v) sodium azide.
Cat. No. 610030	1 mg immunoglobulin in 10 ml PBS solution containing 1.0% (w/v) BSA and 0.09% (w/v) sodium azide.

### Specificity

The antibody recognizes the Mr 250000 and 180000 human tenascin polypeptides in immunoprecipitation and in immunoblots the Mr 250000 polypeptide. The antibody reacts with the fibrinogen-like knob-domain of tenascin protein. The antibody reacts especially with human paraffin sections.

### Application

Immunofluorescence, immunohistochemistry and immunoblotting. Immunohistochemistry with formalin-fixed and paraffin-embedded sections.

### Guidelines for dilutions

Working dilution in immunoblotting is at least 1:1000.

### References

1. Tiitta O. et al. (1992) Am. J. Pathol. 141, 907-913.
2. Tiitta O. et al. (1995) Archs. Oral Biol. 11, 1039-1045.
3. Kaarteenaho-Wiik R. et al. (1996) Am. J. Respir. Crit. Care Med. 154, 511-518.
4. Jahkola T. et al. (1996) Int. J. Cancer 69, 445-447.
5. Jahkola T. et al. (1998) Eur. J. Cancer 34, 1687-1692.
6. Jahkola T. et al. (1998) Br. J. Cancer 78, 1507-1513.
7. Pedrosa-Dömellöf P. et al. (2000) J. Histochem. Cytochem. 48, 201-209.
8. Tuori A. et al. (1997) Graefe's Arch. Clin. Exp. Ophthalmol. 235, 222-229